| The LenSx femtosecond system for cataract surgery, as used at the London Eye Hospital. LenSx, based in California, was acquired in July 2010 by healthcare giant Alcon Labs in a deal which generated a huge return for investors at the time. Alcon is the dominant player in the global cataract surgery devices market with a 43 percent market share, thanks to its leading position in the IOL market as well as a significant presence in both ophthalmic viscoelastic devices and surgical platforms such as LenSx. Credit: LenSx/London Eye Hospital. |
